NASDAQ Framework: Masimo Corporation

Global medical technology company specializing in monitoring solutions 1 2 3.

Masimo Corporation, founded in 1989 by Joe Kiani, is a global medical technology company headquartered in Irvine, California. The company develops, manufactures, and markets a wide array of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices, and consumer health products 4 5 6. Masimo's innovative technologies include the Masimo SET® pulse oximetry, rainbow® Pulse CO-Oximetry, and advanced hemodynamic monitoring solutions, which are widely used in various healthcare settings 7 8. Additionally, Masimo has expanded into consumer health and wellness solutions, offering products like the Masimo W1™ health tracking watch and the Stork™ baby monitor 9. The company also acquired Sound United in 2022, further diversifying its portfolio with premium consumer audio products 10.

4: Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California. View Source5: Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, and patient monitors. Powered by the Masimo Hospital Automation™ platform, Masimo connectivity, automation, and telehealth and telemonitoring solutions are improving and automating care delivery both in the hospital and beyond. In addition, Masimo is home to an expanding array of consumer health and wellness solutions like the Masimo W1™ health tracking watch and Stork™ baby monitor, as well as sound devices from legendary audio brands like Bowers & Wilkins® and Denon®. View Source6: Founded by Joe Kiani in 1989 as a private "garage start-up" company, today Masimo is publicly traded and employs more than 8,000 people worldwide. Licensing agreements allow Masimo medical technologies to work inside monitoring devices from a host of manufacturers, including Philips, Atom, Mindray North America, GE Healthcare, Spacelabs, and Zoll. Throughout its more than 30-year journey, Masimo’s mission – to improve patient outcomes, reduce the cost of care, take noninvasive monitoring to new sites and applications, and improve life – has remained strong. In 2022, Masimo acquired Sound United, a leading developer of premium consumer sound and home integration technologies, adding to its broad portfolio of hospital and home medical technology and wellness solutions. View Source7: Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California. View Source8: Masimo SET® and rainbow® technologies, collectively known as rainbow SET, fuel medical monitoring devices such as Root®, Radical-7®, Radius VSM™, Radius-7®, Rad-97®, Rad-G® with Temperature, and Masimo W1 Medical. These highly versatile devices are configurable for use in a variety of high- and low-acuity hospital settings, from ICUs and surgical suites to postoperative floors, as well as in long-term care facilities and in the case of Rad-97 and Masimo W1, home use. View Source9: Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, and patient monitors. Powered by the Masimo Hospital Automation™ platform, Masimo connectivity, automation, and telehealth and telemonitoring solutions are improving and automating care delivery both in the hospital and beyond. In addition, Masimo is home to an expanding array of consumer health and wellness solutions like the Masimo W1™ health tracking watch and Stork™ baby monitor, as well as sound devices from legendary audio brands like Bowers & Wilkins® and Denon®. View Source10: Founded by Joe Kiani in 1989 as a private "garage start-up" company, today Masimo is publicly traded and employs more than 8,000 people worldwide. Licensing agreements allow Masimo medical technologies to work inside monitoring devices from a host of manufacturers, including Philips, Atom, Mindray North America, GE Healthcare, Spacelabs, and Zoll. Throughout its more than 30-year journey, Masimo’s mission – to improve patient outcomes, reduce the cost of care, take noninvasive monitoring to new sites and applications, and improve life – has remained strong. In 2022, Masimo acquired Sound United, a leading developer of premium consumer sound and home integration technologies, adding to its broad portfolio of hospital and home medical technology and wellness solutions. View Source

YES

Joe Kiani, the founder of Masimo Corporation, is still heavily involved in the company as its CEO and Chairman 11.

11: It’s the latest tug-of-war that could see the ouster of Masimo Chairman and Chief Executive Kiani from the company he founded in 1989 and built it into one of the world’s most successful medtech companies. Politan two years ago built up an 8.9% stake, similar to the size of Kiani’s position. View Source

MEDIUM RISK

Masimo Corporation's financial situation presents a medium risk. While the company has shown strong performance in its first-quarter 2024 results and continues to gain market share with higher contracts with hospitals 12, there are concerns regarding its overdependence on its Signal Extraction Technology (SET) unit and macroeconomic issues 13. Additionally, the company is facing challenges from activist investor Politan, which has led to significant stock price volatility and potential changes in board control 14 15. The company's stock has also experienced a notable decline, losing almost $4 billion in market cap since April 16. Furthermore, Masimo is in discussions to spin off its consumer business, which could impact its financial stability in the short term 17 18.

12: Strong Q1 Results: Masimo’s first-quarter 2024 results buoy optimism. Per management, shipments of non-invasive technology boards and instruments, excluding handheld and fingertip pulse oximeters, totaled 50,400 during the quarter. The company continues to gain market share, along with higher contracts with hospitals. Moreover, it expects shipments to cross 55,000 from the second quarter and reach more than 60,000 in the second half of 2024. Management plans three product launches in 2024, namely Freedom, H1 and the next-generation version of its Root Connectivity platform. View Source13: Masimo Corporation MASI is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) efforts. The optimism, led by a solid first-quarter 2024 performance and its solid product portfolio, is expected to contribute further. However, concerns regarding overdependence on its Signal Extraction Technology (“SET”) unit and macroeconomic issues persist. View Source14: Rift With Politan: Masimo has been facing challenges from activist investor, Politan, since last year. Politan acquired a stake in Masimo last year and added two members to the latter's board. Politan has been trying to gain control of the board since then. Currently, the activist investor has nominated members against MASI's CEO and founder, Joe Kiani, in a proxy vote for electing new board members. A potential loss of control over the board for Kiani may lead to uncertain times. Although Politan is claiming that it will help boost shareholders' value after gaining the board's control, it may take some time to get reflected in the company's share price. View Source15: Rift With Politan: Masimo has been facing challenges from activist investor, Politan, since last year. Politan acquired a stake in Masimo last year and added two members to the latter’s board. Politan has been trying to gain control of the board since then. Currently, the activist investor has nominated members against MASI’s CEO and founder, Joe Kiani, in a proxy vote for electing new board members. A potential loss of control over the board for Kiani may lead to uncertain times. Although Politan is claiming that it will help boost shareholders’ value after gaining the board’s control, it may take some time to get reflected in the company’s share price. View Source16: During the proxy battle, Masimo shares since April have fallen 26%, a loss of almost $4 billion in market cap. The shares now trade around $108.97 and a $5.7 billion market cap (Nasdaq: MASI). View Source17: Consumer Business Spin-off: Masimo is currently in discussion to spin off its Consumer business with an undisclosed third party. The company entered into a non-binding term sheet agreement in May to sell the majority stake in its consumer audio and consumer health businesses. The third party offered to acquire a stake in MASI’s consumer business for a purchase price of $850-$950 million, on a cash and debt-free basis, following the completion of six weeks of due diligence. View Source18: Consumer Business Spin-off: Masimo is currently in discussion to spin off its Consumer business with an undisclosed third party. The company entered into a non-binding term sheet agreement in May to sell the majority stake in its consumer audio and consumer health businesses. The third party offered to acquire a stake in MASI's consumer business for a purchase price of $850-$950 million, on a cash and debt-free basis, following the completion of six weeks of due diligence. View Source

YES

Masimo Corporation is launching new product offerings. The company plans three product launches in 2024, namely Freedom, H1, and the next-generation version of its Root Connectivity platform 19.

19: Strong Q1 Results: Masimo’s first-quarter 2024 results buoy optimism. Per management, shipments of non-invasive technology boards and instruments, excluding handheld and fingertip pulse oximeters, totaled 50,400 during the quarter. The company continues to gain market share, along with higher contracts with hospitals. Moreover, it expects shipments to cross 55,000 from the second quarter and reach more than 60,000 in the second half of 2024. Management plans three product launches in 2024, namely Freedom, H1 and the next-generation version of its Root Connectivity platform. View Source

Masimo Corporation's product roadmap and expansion strategy for 2024 through to 2026 include several key initiatives aimed at bolstering its market position and technological capabilities. The company plans to launch three new products in 2024: the Freedom smart health watch and band, the H1, and the next-generation version of its Root Connectivity platform 20. Additionally, Masimo is in discussions to spin off its consumer business, which includes premium consumer audio and health products, to an undisclosed third party for a purchase price between $850 million and $950 million 21 22. This strategic move is expected to streamline its operations and focus more on its core healthcare segment, which continues to see strong performance and market share growth 23 24.

20: Strong Q1 Results: Masimo’s first-quarter 2024 results buoy optimism. Per management, shipments of non-invasive technology boards and instruments, excluding handheld and fingertip pulse oximeters, totaled 50,400 during the quarter. The company continues to gain market share, along with higher contracts with hospitals. Moreover, it expects shipments to cross 55,000 from the second quarter and reach more than 60,000 in the second half of 2024. Management plans three product launches in 2024, namely Freedom, H1 and the next-generation version of its Root Connectivity platform. View Source21: Consumer Business Spin-off: Masimo is currently in discussion to spin off its Consumer business with an undisclosed third party. The company entered into a non-binding term sheet agreement in May to sell the majority stake in its consumer audio and consumer health businesses. The third party offered to acquire a stake in MASI’s consumer business for a purchase price of $850-$950 million, on a cash and debt-free basis, following the completion of six weeks of due diligence. View Source22: Consumer Business Spin-off: Masimo is currently in discussion to spin off its Consumer business with an undisclosed third party. The company entered into a non-binding term sheet agreement in May to sell the majority stake in its consumer audio and consumer health businesses. The third party offered to acquire a stake in MASI's consumer business for a purchase price of $850-$950 million, on a cash and debt-free basis, following the completion of six weeks of due diligence. View Source23: Strong Q1 Results: Masimo’s first-quarter 2024 results buoy optimism. Per management, shipments of non-invasive technology boards and instruments, excluding handheld and fingertip pulse oximeters, totaled 50,400 during the quarter. The company continues to gain market share, along with higher contracts with hospitals. Moreover, it expects shipments to cross 55,000 from the second quarter and reach more than 60,000 in the second half of 2024. Management plans three product launches in 2024, namely Freedom, H1 and the next-generation version of its Root Connectivity platform. View Source24: Consumer Business Spin-off: Masimo is currently in discussion to spin off its Consumer business with an undisclosed third party. The company entered into a non-binding term sheet agreement in May to sell the majority stake in its consumer audio and consumer health businesses. The third party offered to acquire a stake in MASI’s consumer business for a purchase price of $850-$950 million, on a cash and debt-free basis, following the completion of six weeks of due diligence. View Source

Sources

1: Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California. View Source2: Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, and patient monitors. Powered by the Masimo Hospital Automation™ platform, Masimo connectivity, automation, and telehealth and telemonitoring solutions are improving and automating care delivery both in the hospital and beyond. In addition, Masimo is home to an expanding array of consumer health and wellness solutions like the Masimo W1™ health tracking watch and Stork™ baby monitor, as well as sound devices from legendary audio brands like Bowers & Wilkins® and Denon®. View Source3: Masimo Corp is a global technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies. View Source4: Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California. View Source5: Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, and patient monitors. Powered by the Masimo Hospital Automation™ platform, Masimo connectivity, automation, and telehealth and telemonitoring solutions are improving and automating care delivery both in the hospital and beyond. In addition, Masimo is home to an expanding array of consumer health and wellness solutions like the Masimo W1™ health tracking watch and Stork™ baby monitor, as well as sound devices from legendary audio brands like Bowers & Wilkins® and Denon®. View Source6: Founded by Joe Kiani in 1989 as a private "garage start-up" company, today Masimo is publicly traded and employs more than 8,000 people worldwide. Licensing agreements allow Masimo medical technologies to work inside monitoring devices from a host of manufacturers, including Philips, Atom, Mindray North America, GE Healthcare, Spacelabs, and Zoll. Throughout its more than 30-year journey, Masimo’s mission – to improve patient outcomes, reduce the cost of care, take noninvasive monitoring to new sites and applications, and improve life – has remained strong. In 2022, Masimo acquired Sound United, a leading developer of premium consumer sound and home integration technologies, adding to its broad portfolio of hospital and home medical technology and wellness solutions. View Source7: Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California. View Source8: Masimo SET® and rainbow® technologies, collectively known as rainbow SET, fuel medical monitoring devices such as Root®, Radical-7®, Radius VSM™, Radius-7®, Rad-97®, Rad-G® with Temperature, and Masimo W1 Medical. These highly versatile devices are configurable for use in a variety of high- and low-acuity hospital settings, from ICUs and surgical suites to postoperative floors, as well as in long-term care facilities and in the case of Rad-97 and Masimo W1, home use. View Source9: Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, and patient monitors. Powered by the Masimo Hospital Automation™ platform, Masimo connectivity, automation, and telehealth and telemonitoring solutions are improving and automating care delivery both in the hospital and beyond. In addition, Masimo is home to an expanding array of consumer health and wellness solutions like the Masimo W1™ health tracking watch and Stork™ baby monitor, as well as sound devices from legendary audio brands like Bowers & Wilkins® and Denon®. View Source10: Founded by Joe Kiani in 1989 as a private "garage start-up" company, today Masimo is publicly traded and employs more than 8,000 people worldwide. Licensing agreements allow Masimo medical technologies to work inside monitoring devices from a host of manufacturers, including Philips, Atom, Mindray North America, GE Healthcare, Spacelabs, and Zoll. Throughout its more than 30-year journey, Masimo’s mission – to improve patient outcomes, reduce the cost of care, take noninvasive monitoring to new sites and applications, and improve life – has remained strong. In 2022, Masimo acquired Sound United, a leading developer of premium consumer sound and home integration technologies, adding to its broad portfolio of hospital and home medical technology and wellness solutions. View Source11: It’s the latest tug-of-war that could see the ouster of Masimo Chairman and Chief Executive Kiani from the company he founded in 1989 and built it into one of the world’s most successful medtech companies. Politan two years ago built up an 8.9% stake, similar to the size of Kiani’s position. View Source12: Strong Q1 Results: Masimo’s first-quarter 2024 results buoy optimism. Per management, shipments of non-invasive technology boards and instruments, excluding handheld and fingertip pulse oximeters, totaled 50,400 during the quarter. The company continues to gain market share, along with higher contracts with hospitals. Moreover, it expects shipments to cross 55,000 from the second quarter and reach more than 60,000 in the second half of 2024. Management plans three product launches in 2024, namely Freedom, H1 and the next-generation version of its Root Connectivity platform. View Source13: Masimo Corporation MASI is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) efforts. The optimism, led by a solid first-quarter 2024 performance and its solid product portfolio, is expected to contribute further. However, concerns regarding overdependence on its Signal Extraction Technology (“SET”) unit and macroeconomic issues persist. View Source14: Rift With Politan: Masimo has been facing challenges from activist investor, Politan, since last year. Politan acquired a stake in Masimo last year and added two members to the latter's board. Politan has been trying to gain control of the board since then. Currently, the activist investor has nominated members against MASI's CEO and founder, Joe Kiani, in a proxy vote for electing new board members. A potential loss of control over the board for Kiani may lead to uncertain times. Although Politan is claiming that it will help boost shareholders' value after gaining the board's control, it may take some time to get reflected in the company's share price. View Source15: Rift With Politan: Masimo has been facing challenges from activist investor, Politan, since last year. Politan acquired a stake in Masimo last year and added two members to the latter’s board. Politan has been trying to gain control of the board since then. Currently, the activist investor has nominated members against MASI’s CEO and founder, Joe Kiani, in a proxy vote for electing new board members. A potential loss of control over the board for Kiani may lead to uncertain times. Although Politan is claiming that it will help boost shareholders’ value after gaining the board’s control, it may take some time to get reflected in the company’s share price. View Source16: During the proxy battle, Masimo shares since April have fallen 26%, a loss of almost $4 billion in market cap. The shares now trade around $108.97 and a $5.7 billion market cap (Nasdaq: MASI). View Source17: Consumer Business Spin-off: Masimo is currently in discussion to spin off its Consumer business with an undisclosed third party. The company entered into a non-binding term sheet agreement in May to sell the majority stake in its consumer audio and consumer health businesses. The third party offered to acquire a stake in MASI’s consumer business for a purchase price of $850-$950 million, on a cash and debt-free basis, following the completion of six weeks of due diligence. View Source18: Consumer Business Spin-off: Masimo is currently in discussion to spin off its Consumer business with an undisclosed third party. The company entered into a non-binding term sheet agreement in May to sell the majority stake in its consumer audio and consumer health businesses. The third party offered to acquire a stake in MASI's consumer business for a purchase price of $850-$950 million, on a cash and debt-free basis, following the completion of six weeks of due diligence. View Source19: Strong Q1 Results: Masimo’s first-quarter 2024 results buoy optimism. Per management, shipments of non-invasive technology boards and instruments, excluding handheld and fingertip pulse oximeters, totaled 50,400 during the quarter. The company continues to gain market share, along with higher contracts with hospitals. Moreover, it expects shipments to cross 55,000 from the second quarter and reach more than 60,000 in the second half of 2024. Management plans three product launches in 2024, namely Freedom, H1 and the next-generation version of its Root Connectivity platform. View Source20: Strong Q1 Results: Masimo’s first-quarter 2024 results buoy optimism. Per management, shipments of non-invasive technology boards and instruments, excluding handheld and fingertip pulse oximeters, totaled 50,400 during the quarter. The company continues to gain market share, along with higher contracts with hospitals. Moreover, it expects shipments to cross 55,000 from the second quarter and reach more than 60,000 in the second half of 2024. Management plans three product launches in 2024, namely Freedom, H1 and the next-generation version of its Root Connectivity platform. View Source21: Consumer Business Spin-off: Masimo is currently in discussion to spin off its Consumer business with an undisclosed third party. The company entered into a non-binding term sheet agreement in May to sell the majority stake in its consumer audio and consumer health businesses. The third party offered to acquire a stake in MASI’s consumer business for a purchase price of $850-$950 million, on a cash and debt-free basis, following the completion of six weeks of due diligence. View Source22: Consumer Business Spin-off: Masimo is currently in discussion to spin off its Consumer business with an undisclosed third party. The company entered into a non-binding term sheet agreement in May to sell the majority stake in its consumer audio and consumer health businesses. The third party offered to acquire a stake in MASI's consumer business for a purchase price of $850-$950 million, on a cash and debt-free basis, following the completion of six weeks of due diligence. View Source23: Strong Q1 Results: Masimo’s first-quarter 2024 results buoy optimism. Per management, shipments of non-invasive technology boards and instruments, excluding handheld and fingertip pulse oximeters, totaled 50,400 during the quarter. The company continues to gain market share, along with higher contracts with hospitals. Moreover, it expects shipments to cross 55,000 from the second quarter and reach more than 60,000 in the second half of 2024. Management plans three product launches in 2024, namely Freedom, H1 and the next-generation version of its Root Connectivity platform. View Source24: Consumer Business Spin-off: Masimo is currently in discussion to spin off its Consumer business with an undisclosed third party. The company entered into a non-binding term sheet agreement in May to sell the majority stake in its consumer audio and consumer health businesses. The third party offered to acquire a stake in MASI’s consumer business for a purchase price of $850-$950 million, on a cash and debt-free basis, following the completion of six weeks of due diligence. View Source